Welgene Biotech Co.,Ltd. (TPEX:6661)
Taiwan · Delayed Price · Currency is TWD 18.60
-0.50 (-2.62%)
At close: Feb 11, 2026
Welgene Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 365.75 | 322.55 | 280.55 | 321.9 | 312.65 | 398.1 | |
Revenue Growth (YoY) | 18.54% | 14.97% | -12.85% | 2.96% | -21.46% | -4.64% |
Cost of Revenue | 212.91 | 186.71 | 160.83 | 180.1 | 179.38 | 235.8 |
Gross Profit | 152.85 | 135.84 | 119.72 | 141.8 | 133.27 | 162.3 |
Selling, General & Admin | 126.44 | 110.69 | 100.43 | 104.3 | 97.13 | 104.18 |
Research & Development | 26.37 | 25.85 | 24.15 | 21.63 | 21.64 | 22 |
Operating Expenses | 152.99 | 136.69 | 123.98 | 124.52 | 118.97 | 127.07 |
Operating Income | -0.14 | -0.85 | -4.26 | 17.29 | 14.3 | 35.22 |
Interest Expense | -3.19 | -2.97 | -2.62 | -0.28 | -0.43 | -0.65 |
Interest & Investment Income | 2.09 | 1.46 | 1.46 | 0.51 | 0.17 | 0.21 |
Earnings From Equity Investments | - | - | - | - | -2.89 | 1.38 |
Currency Exchange Gain (Loss) | -0.4 | 0.25 | 0.01 | -0.02 | - | 0.18 |
Other Non Operating Income (Expenses) | 3.55 | 3 | 1.69 | 0.25 | 0.18 | 0.46 |
EBT Excluding Unusual Items | 1.9 | 0.88 | -3.73 | 17.74 | 11.34 | 36.8 |
Gain (Loss) on Sale of Investments | - | - | - | -4.19 | 5.04 | - |
Gain (Loss) on Sale of Assets | 0.18 | 0.37 | -0.11 | - | 0.21 | 0.33 |
Other Unusual Items | - | - | 0.81 | - | - | - |
Pretax Income | 2.09 | 1.25 | -3.03 | 13.55 | 16.6 | 37.14 |
Income Tax Expense | 0.64 | 0.54 | 0.11 | 4.01 | 2.89 | 7.36 |
Earnings From Continuing Operations | 1.45 | 0.71 | -3.15 | 9.54 | 13.7 | 29.78 |
Minority Interest in Earnings | 0.19 | 0.4 | 0.5 | 0.01 | -0 | -0 |
Net Income | 1.64 | 1.11 | -2.65 | 9.55 | 13.7 | 29.77 |
Net Income to Common | 1.64 | 1.11 | -2.65 | 9.55 | 13.7 | 29.77 |
Net Income Growth | - | - | - | -30.29% | -53.98% | -3.55% |
Shares Outstanding (Basic) | 23 | 23 | 23 | 23 | 23 | 21 |
Shares Outstanding (Diluted) | 23 | 23 | 23 | 23 | 23 | 21 |
Shares Change (YoY) | - | - | -0.10% | 0.93% | 10.99% | -0.01% |
EPS (Basic) | 0.07 | 0.05 | -0.11 | 0.41 | 0.59 | 1.44 |
EPS (Diluted) | 0.07 | 0.05 | -0.11 | 0.41 | 0.59 | 1.43 |
EPS Growth | - | - | - | -30.53% | -58.74% | -3.38% |
Free Cash Flow | 28.49 | 51.27 | -28.1 | 24.57 | 6.87 | 35.86 |
Free Cash Flow Per Share | 1.22 | 2.20 | -1.21 | 1.05 | 0.30 | 1.72 |
Dividend Per Share | - | - | - | 0.180 | 0.480 | 1.102 |
Dividend Growth | - | - | - | -62.50% | -56.44% | -17.84% |
Gross Margin | 41.79% | 42.11% | 42.67% | 44.05% | 42.63% | 40.77% |
Operating Margin | -0.04% | -0.27% | -1.52% | 5.37% | 4.57% | 8.85% |
Profit Margin | 0.45% | 0.34% | -0.94% | 2.97% | 4.38% | 7.48% |
Free Cash Flow Margin | 7.79% | 15.90% | -10.02% | 7.63% | 2.20% | 9.01% |
EBITDA | 14.04 | 14.54 | 9.48 | 24.44 | 22.23 | 42.28 |
EBITDA Margin | 3.84% | 4.51% | 3.38% | 7.59% | 7.11% | 10.62% |
D&A For EBITDA | 14.19 | 15.39 | 13.74 | 7.15 | 7.93 | 7.05 |
EBIT | -0.14 | -0.85 | -4.26 | 17.29 | 14.3 | 35.22 |
EBIT Margin | -0.04% | -0.27% | -1.52% | 5.37% | 4.57% | 8.85% |
Effective Tax Rate | 30.57% | 43.52% | - | 29.58% | 17.43% | 19.82% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.